Hypertension: Difference between revisions
Jump to navigation
Jump to search
imported>Peter A. Lipson |
imported>Peter A. Lipson |
||
Line 13: | Line 13: | ||
==References== | ==References== | ||
*http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf | *http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf | ||
*(Formatting needed)"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group | *(Formatting needed)"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.JAMA. 2002;288:2981-2997. | ||
JAMA. 2002;288:2981-2997. | |||
[[Category:Health Sciences Workgroup]] | [[Category:Health Sciences Workgroup]] |
Revision as of 21:25, 27 April 2007
Hypertension is a multisystem disease whose hallmark is the elevation of blood pressure.
Definition
Epidemiology
Etiology
Pathophysiology
Diagnosis & Natural History
Treatment
References
- http://www.nhlbi.nih.gov/guidelines/hypertension/jnc7full.pdf
- (Formatting needed)"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.JAMA. 2002;288:2981-2997.